Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100

被引：7

作者：

Aragon-Ching, J. B. ^{[1
]}

Grivas, P. ^{[2
]}

Loriot, Y. ^{[3
]}

Bellmunt, J. ^{[4
]}

Wang, J. ^{[5
]}

Michelon, E. ^{[6
]}

di Pietro, A. ^{[7
]}

Powles, T. B. ^{[8
]}

Sridhar, S. ^{[9
]}

机构：

[1] Inova Schar Canc Inst, GU Oncol, Fairfax, VA USA

[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Med Oncol Dept, Seattle, WA USA

[3] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, INSERMU981, Villejuif, France

[4] Harvard Med Sch, Dept Med Oncol, Beth Israel Deaconess Med Ctr, Boston, MA USA

[5] Pfizer, Biostat, Cambridge, MA USA

[6] Pfizer, Safety Surveillance & Risk Management, New York, NY USA

[7] Pfizer SRL, Clin Dev Oncol, Milan, Italy

[8] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Dept Genitourinary Oncol,Expt Canc Med Ctr, London, England

[9] Univ Hlth Network, Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.1838

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1760P

引用

页码：S1343 / S1343

页数：1